AstraZeneca: a medicine worth taking?
Are AstraZeneca’s shares worth buying? Patent fears have hit the company, but investors would be well advised to look beyond the court room dramas.
AstraZeneca's (AZN, 2,687p) shares are like an "unpalatable but beneficial medicine", says Philip Aldrick in The Daily Telegraph: buying them may leave an unpleasant taste in the mouth, but it could well be worth doing anyway.
The unpleasantness is due to "jitters" over future earnings prospects after a US court invalidated patents on one of its $1bn-plus "blockbuster" drugs, Toprol XL, 19 months before the patents were due to expire.
It is the first time Europe's third-largest pharmaceutical firm has lost such a challenge, and the ruling casts doubt over AstraZeneca's earnings guidance of $3.40-$3.60 a share, says Richard Irving in The Times, which assumes the judgment "can be overturned". The company aims to challenge the ruling, but most analysts "hold out little hope" it can overturn the verdict on appeal, says Ian Lyall in The Daily Mail.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Nor is Toprol the only drug under threat from generic producers. Challenges have also been made to AstraZeneca's biggest product, top-selling heartburn drug Nexium, and another of its "fabulous five" drugs, anti-psychotic Seroquel (which, with Toprol, accounts for nearly 40% of company revenues). It has also seen two potential blockbusters Iressa and Exanta "fail at the final [regulatory] hurdle".
But things aren't as bad as they seem, says Aldrick. None of the competition has yet won FDA approval for a generic version of Toprol. And AstraZeneca has "a strong cash position", which it is using to rebuild its drug pipeline via a series of licensing and corporate deals, with as many as "nine medicines in final Phase III trials within 18 months". This is not a cheap process, but is already well discounted in Astra's share price, which (on a p/e of 14.3 times for next year) stands at a 17% discount to the sector. If that fails, says Lyall, then there is always the hope of a bid from either Pfizer or Glaxo. "A cautious buy."
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Charles has previously written for the MoneyWeek, giving readers his share tips regularly and covering other topics on the side such as stock markets and the economy. He has also written for The Business, Shares, Investors Chronicle and The Evening Standard, and Charles has presented on LBC and been a guest on BBC One and BBC World. Aside from his journalist background, Charles graduated as a chemist from the University of Oxford specialising in ligand gated ion channels.
-
How to invest in nuclear power
We need nuclear power to go green, says Dominic Frisby. But there is a better option than huge power stations
By Dominic Frisby Published
-
Chase slashes its easy-access savings rate – is it time to switch?
The Chase easy-access savings account has proved popular with savers thanks to its competitive rate and bonus deals. But, as the rate has dropped, has it lost its charm?
By Katie Williams Published